AstraZeneca Results Presentation Deck

Reported profit and loss Total revenue - product sales - collaboration revenue Gross margin Operating expenses¹ - R&D² expenses - SG&A³ expenses Other operating income Operating profit Tax rate EPS Q1 2021 $m 7,320 7,257 63 74.3% 4,741 1,713 2,929 1,180 1,895 2.9% $1.19 change % 11 11 42 (2.7) pp4 9 19 4 145 54 97 % total revenue 100 99 1 65 23 40 16 26 Absolute values at actual exchange rates; changes at CER. Gross margin excludes the impact of collaboration revenue and any associated costs, thereby reflecting the underlying performance of product sales. 1. Includes distribution expenses 2. Research and development 3. Sales, general and administration 4. Percentage points. 20 B

View entire presentation